1. Home
  2. CRGX vs ECX Comparison

CRGX vs ECX Comparison

Compare CRGX & ECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRGX
  • ECX
  • Stock Information
  • Founded
  • CRGX 2021
  • ECX 2017
  • Country
  • CRGX United States
  • ECX China
  • Employees
  • CRGX N/A
  • ECX N/A
  • Industry
  • CRGX
  • ECX EDP Services
  • Sector
  • CRGX
  • ECX Technology
  • Exchange
  • CRGX Nasdaq
  • ECX Nasdaq
  • Market Cap
  • CRGX 628.6M
  • ECX 584.9M
  • IPO Year
  • CRGX 2023
  • ECX N/A
  • Fundamental
  • Price
  • CRGX $3.86
  • ECX $1.61
  • Analyst Decision
  • CRGX Hold
  • ECX
  • Analyst Count
  • CRGX 7
  • ECX 0
  • Target Price
  • CRGX $4.67
  • ECX N/A
  • AVG Volume (30 Days)
  • CRGX 1.9M
  • ECX 1.0M
  • Earning Date
  • CRGX 03-20-2025
  • ECX 02-26-2025
  • Dividend Yield
  • CRGX N/A
  • ECX N/A
  • EPS Growth
  • CRGX N/A
  • ECX N/A
  • EPS
  • CRGX N/A
  • ECX N/A
  • Revenue
  • CRGX N/A
  • ECX $778,608,168.00
  • Revenue This Year
  • CRGX N/A
  • ECX $20.12
  • Revenue Next Year
  • CRGX N/A
  • ECX $32.70
  • P/E Ratio
  • CRGX N/A
  • ECX N/A
  • Revenue Growth
  • CRGX N/A
  • ECX 25.45
  • 52 Week Low
  • CRGX $3.00
  • ECX $0.96
  • 52 Week High
  • CRGX $33.92
  • ECX $3.09
  • Technical
  • Relative Strength Index (RSI)
  • CRGX 20.88
  • ECX 40.06
  • Support Level
  • CRGX $3.00
  • ECX $1.59
  • Resistance Level
  • CRGX $3.88
  • ECX $1.79
  • Average True Range (ATR)
  • CRGX 0.92
  • ECX 0.12
  • MACD
  • CRGX -1.00
  • ECX -0.02
  • Stochastic Oscillator
  • CRGX 5.99
  • ECX 21.05

About CRGX CARGO Therapeutics Inc.

Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.

About ECX ECARX Holdings Inc. Ordinary shares

ECARX Holdings Inc is engaged in the sales of system-on-chip core modules, automotive computing platform products, and software stacks as well as the provision of research and development services primarily in the People's Republic of China. The company's core products include infotainment head units, digital cockpits, vehicle chip-set solutions, a core operating system, and an integrated software stack. Beyond this, ECARX is developing a full-stack automotive computing platform. It is engaged in automotive intelligence and networking.

Share on Social Networks: